Trial · NCT04039412
Comparison Between Quadruple Regimens for Helicobacter Pylori Infection in Egypt
NCT04039412, Phase 4, Completed, Ayman Magd Eldin Mohammad Sadek; results first posted 2019-11-26
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Comparison Between Quadruple Regimens for Helicobacter Pylori Infection in Egypt. Trials, record NCT04039412. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04039412
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Comparison Between Quadruple Regimens for Helicobacter Pylori Infection in Egypt
- NCT number
- NCT04039412
- Status
- Completed
- Phases
- Phase 4
- Enrollment
- 330 participants, actual
- Lead sponsor
- Ayman Magd Eldin Mohammad Sadek
- Conditions
- Helicobacter Pylori Infection
- Interventions
- Hybrid regimen, Reverse hybrid regimen, Levofloxacin quadruple regimen
- First posted
- 2019-07-31
- Last updated
- 2019-11-26
- Results first posted
- 2019-11-26
Source ClinicalTrials.gov
Registered outcomes3
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Percentage of Helicobacter Pylori Infection Cure | 40-44 days | Measuring the curative rate of each regimen by a fecal antigen test |
| Primary | Incidence of Treatment-Emergent Adverse Events | 10-14 days | Questionnaire to measure the number of Participants with Treatment-Emergent Adverse Events |
| Secondary | Rate of Helicobacter Pylori Treatment Completion | 10-14 days | Questionnaire to evaluate the compliance with each treatment regimen |
Source ClinicalTrials.gov
Outcomes3
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Percentage of Helicobacter Pylori Infection Cure | 40-44 days | Participants | COUNT_OF_PARTICIPANTS | |
| PRIMARY | Incidence of Treatment-Emergent Adverse Events | 10-14 days | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Rate of Helicobacter Pylori Treatment Completion | 10-14 days | Participants | COUNT_OF_PARTICIPANTS |
Source ClinicalTrials.gov
Results by group9
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percentage of Helicobacter Pylori Infection Cure | (1) Reverse Hybrid Regimen | 102 | Participants | ||
| Percentage of Helicobacter Pylori Infection Cure | (2) Hybrid Regimen | 101 | Participants | ||
| Percentage of Helicobacter Pylori Infection Cure | (3) Levofloxacin Quadruple Regimen | 91 | Participants | ||
| Incidence of Treatment-Emergent Adverse Events | (1) Reverse Hybrid Regimen | 49 | Participants | ||
| Incidence of Treatment-Emergent Adverse Events | (2) Hybrid Regimen | 58 | Participants | ||
| Incidence of Treatment-Emergent Adverse Events | (3) Levofloxacin Quadruple Regimen | 44 | Participants | ||
| Rate of Helicobacter Pylori Treatment Completion | (1) Reverse Hybrid Regimen | 109 | Participants | ||
| Rate of Helicobacter Pylori Treatment Completion | (2) Hybrid Regimen | 107 | Participants | ||
| Rate of Helicobacter Pylori Treatment Completion | (3) Levofloxacin Quadruple Regimen | 108 | Participants |
Source ClinicalTrials.gov
Participant flow9
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | (1) Reverse Hybrid Regimen | 110 | |
| Overall Study | STARTED | (2) Hybrid Regimen | 110 | |
| Overall Study | STARTED | (3) Levofloxacin Quadruple Regimen | 110 | |
| Overall Study | COMPLETED | (1) Reverse Hybrid Regimen | 109 | |
| Overall Study | COMPLETED | (2) Hybrid Regimen | 107 | |
| Overall Study | COMPLETED | (3) Levofloxacin Quadruple Regimen | 108 | |
| Overall Study | NOT COMPLETED | (1) Reverse Hybrid Regimen | 1 | |
| Overall Study | NOT COMPLETED | (2) Hybrid Regimen | 3 | |
| Overall Study | NOT COMPLETED | (3) Levofloxacin Quadruple Regimen | 2 |
Source ClinicalTrials.gov
Adverse events6
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Gastrointestinal symptoms | Gastrointestinal disorders | (1) Reverse Hybrid Regimen | 41 | 110 | 41 |
| other | Gastrointestinal symptoms | Gastrointestinal disorders | (2) Hybrid Regimen | 50 | 110 | 50 |
| other | Gastrointestinal symptoms | Gastrointestinal disorders | (3) Levofloxacin Quadruple Regimen | 37 | 110 | 37 |
| other | General symptoms | General disorders | (1) Reverse Hybrid Regimen | 8 | 110 | 8 |
| other | General symptoms | General disorders | (2) Hybrid Regimen | 8 | 110 | 8 |
| other | General symptoms | General disorders | (3) Levofloxacin Quadruple Regimen | 7 | 110 | 7 |
Source ClinicalTrials.gov
Adverse event totals9
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | (1) Reverse Hybrid Regimen | 0 | 109 |
| Total, all-cause mortality | (2) Hybrid Regimen | 0 | 107 |
| Total, all-cause mortality | (3) Levofloxacin Quadruple Regimen | 0 | 108 |
| Total, other adverse events | (1) Reverse Hybrid Regimen | 49 | 110 |
| Total, other adverse events | (2) Hybrid Regimen | 58 | 110 |
| Total, other adverse events | (3) Levofloxacin Quadruple Regimen | 44 | 110 |
| Total, serious adverse events | (1) Reverse Hybrid Regimen | 0 | 109 |
| Total, serious adverse events | (2) Hybrid Regimen | 0 | 107 |
| Total, serious adverse events | (3) Levofloxacin Quadruple Regimen | 0 | 108 |
Source ClinicalTrials.gov
Papers14
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04039412
GET https://conductscience.org/api/trials/v1/NCT04039412/registered